Article
Rifampicin and rifabutin resistance in 1000 <i>Mycobacterium tuberculosis</i> clinical isolates
2018-09-25
Abstract excerpt
<h4>Synopsis</h4> Drug resistant tuberculosis (TB) remains a public health challenge with limited treatment options and high associated mortality. Rifamycins are among the most potent anti-TB drugs, and the loss of susceptibility to these agents, a hallmark of MDR TB, is considered a substantial therapeutic challenge. Rifamycins are known to target the RpoB subunit of RNA polymerase; however, our understanding of...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 0a886ff6-a635-5527-823b-ff9be7d979b1
- DOI
- 10.1101/425652
